Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
| ▸ | CETP | P11597 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3239419 | 0.94 | ALDH1A1 (0.38) | ALDH1A1SMN1; SMN2FFAR3HSD11B1CETP | |
| SCHEMBL19383627 | 0.94 | ALDH1A1 (0.38) | ALDH1A1SMN1; SMN2FFAR3HSD11B1CETP | |
| SCHEMBL3909314 | 0.91 | FFAR3 (0.36) | ALDH1A1SMN1; SMN2FFAR3HSD11B1CETP | |
| SCHEMBL1143457 | 0.82 | — | — | |
| SCHEMBL23011781 | 0.73 | ALDH1A1 (0.35) | ALDH1A1SMN1; SMN2CETP | |
| SCHEMBL7080167 | 0.73 | ALDH1A1 (0.39) | ALDH1A1SMN1; SMN2FFAR3HSD11B1CETP | |
| SCHEMBL7080172 | 0.73 | ALDH1A1 (0.39) | ALDH1A1SMN1; SMN2FFAR3HSD11B1CETP | |
| SCHEMBL13457323 | 0.73 | FFAR3 (0.62) | ALDH1A1SMN1; SMN2FFAR3HSD11B1CETP | |
| SCHEMBL22550126 | 0.73 | ALDH1A1 (0.39) | ALDH1A1SMN1; SMN2FFAR3HSD11B1CETP | |
| SCHEMBL12883183 | 0.73 | ALDH1A1 (0.39) | ALDH1A1SMN1; SMN2FFAR3HSD11B1CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9802939-B2 | Macrocycles as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-31 | — | — | US | disclosed |
| US-20150112058-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150112058-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F11 | ALDH1A1 4598/4885SMN1; SMN2 3689/4885FFAR3 3003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.